Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Duda

Showing results (281-290 of 338) with videos related to

Pageof 34
Sort By:
Journal of the National Cancer Institute|August 1, 2013
Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progressionShom Goel, Nisha Gupta, Brian P Walcott, et al.
Gut|January 3, 2023
Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrencesShuling Chen, Cheng Huang, Guanrui Liao, et al.
The Oncologist|October 30, 2016
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer PatientsSara M Tolaney, David R Ziehr, Hao Guo, et al.
Oncology|July 19, 2023
Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular CarcinomaShadi Chamseddine, Yehia I Mohamed, Sunyoung S Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2015
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patientsSara M Tolaney, Yves Boucher, Dan G Duda, et al.
JCO Global Oncology|April 22, 2020
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated CholangiocarcinomaSarinya Kongpetch, Apinya Jusakul, Jing Quan Lim, et al.
Theranostics|February 22, 2018
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor developmentYun-Chieh Sung, Ya-Chi Liu, Po-Han Chao, et al.
NPJ Precision Oncology|December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survivalOvidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
International Journal of Radiation Oncology, Biology, Physics|June 4, 2018
Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver CancerClemens Grassberger, Theodore S Hong, Tai Hato, et al.
Oncotarget|December 6, 2022
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patientsYehia I Mohamed, Dan G Duda, Muhammad O Awiwi, et al.
Pageof 34

Showing results (281-290 of 338) with videos related to

Sort By:
Pageof 34
Journal of the National Cancer Institute|August 1, 2013
Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progressionShom Goel, Nisha Gupta, Brian P Walcott, et al.
Gut|January 3, 2023
Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrencesShuling Chen, Cheng Huang, Guanrui Liao, et al.
The Oncologist|October 30, 2016
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer PatientsSara M Tolaney, David R Ziehr, Hao Guo, et al.
Oncology|July 19, 2023
Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular CarcinomaShadi Chamseddine, Yehia I Mohamed, Sunyoung S Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2015
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patientsSara M Tolaney, Yves Boucher, Dan G Duda, et al.
JCO Global Oncology|April 22, 2020
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated CholangiocarcinomaSarinya Kongpetch, Apinya Jusakul, Jing Quan Lim, et al.
Theranostics|February 22, 2018
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor developmentYun-Chieh Sung, Ya-Chi Liu, Po-Han Chao, et al.
NPJ Precision Oncology|December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survivalOvidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
International Journal of Radiation Oncology, Biology, Physics|June 4, 2018
Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver CancerClemens Grassberger, Theodore S Hong, Tai Hato, et al.
Oncotarget|December 6, 2022
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patientsYehia I Mohamed, Dan G Duda, Muhammad O Awiwi, et al.
Pageof 34